Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PANK3 | Q9H999 | 6/20 | 0.43 |
| ▸ | SMO | Q99835 | 2/20 | 0.42 |
| ▸ | OGA | O60502 | 6/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23483100 | 0.86 | MEN1 (0.37) | PANK3SMOMAPTALDH1A1CYP3A4 | |
| SCHEMBL19001135 | 0.78 | OGA (0.44) | PANK3SMOOGA | |
| SCHEMBL20443650 | 0.78 | PANK3 (0.42) | PANK3SMOOGAMAPT | |
| SCHEMBL10127337 | 0.71 | HTR3A (0.49) | PANK3OGAALDH1A1 | |
| SCHEMBL22005788 | 0.71 | OGA (0.40) | PANK3OGA | |
| SCHEMBL14349207 | 0.70 | PANK3 (0.46) | PANK3SMOOGAMAPTALDH1A1 | |
| SCHEMBL13466366 | 0.70 | CNR2 (0.48) | PANK3OGAMAPTALDH1A1 | |
| SCHEMBL22006730 | 0.70 | ALDH1A1 (0.40) | PANK3HSD11B1MAPTALDH1A1GAA | |
| SCHEMBL14924078 | 0.70 | OGA (0.50) | PANK3OGA | |
| SCHEMBL4547927 | 0.69 | CNR2 (0.50) | PANK3OGAMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11236051-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20210009528-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Arvinas, Inc. | 2021-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009528-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | PANK3 3092/4885SMO 409/4885OGA 1240/4885 |
| US-11236051-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, ADRM1, CRBN | PANK3 3092/4885SMO 409/4885OGA 1240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.